ARTICLE | Clinical News
Trebananib regulatory update
January 27, 2014 8:00 AM UTC
The European Commission granted Orphan Drug designation to Amgen's trebananib to treat ovarian cancer. The recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins is in Phase III tes...